Brookline Capital Initiates Coverage On Ernexa Therapeutics with Buy Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Positive 57.6%

Neg 0% Neu 0% Pos 57.6%

Brookline Capital initiates coverage on Ernexa Therapeutics (NASDAQ:ERNA) with a Buy rating and announces Price Target of $30.